<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900094</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000276589</org_study_id>
    <secondary_id>U01CA084982</secondary_id>
    <secondary_id>P30CA046592</secondary_id>
    <secondary_id>CCUM-0003</secondary_id>
    <nct_id>NCT00900094</nct_id>
  </id_info>
  <brief_title>UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer</brief_title>
  <acronym>IRB 2000-294</acronym>
  <official_title>Proteomics Biomarker Development Laboratory (Aka IRB 1999-514)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with&#xD;
      cancer and blood from healthy participants may help doctors learn more about changes that may&#xD;
      occur in DNA and identify biomarkers related to cancer.&#xD;
&#xD;
      PURPOSE: This laboratory study is looking at cancer-related protein biomarkers in the blood&#xD;
      and tumor tissue of patients with cancer and in the blood of healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Identify tumor antigens that induce a humoral response in patients with cancer.&#xD;
&#xD;
        -  Identify tumor-secreted proteins by special analysis in culture, and evaluate their&#xD;
           expression patterns in tumors and preneoplastic lesions to further assess their&#xD;
           potential specificity.&#xD;
&#xD;
        -  Determine serum positivity and specificity of potential markers for early detection of&#xD;
           cancer.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients and healthy participants undergo blood collection. Patients with suspected or newly&#xD;
      diagnosed disease undergo a second blood collection between 4-10 weeks after surgery (but&#xD;
      before any additional cytotoxic therapy or radiotherapy) provided they had a surgical&#xD;
      resection with negative margin. All patients are asked questions about family history of&#xD;
      cancer, the development of their cancer, other medical history, past and present smoking&#xD;
      history, and menstrual period for females.&#xD;
&#xD;
      DNA is extracted from the blood and from patient tumor tissue samples obtained during&#xD;
      surgery. Immunohistochemistry (including polymerase chain reaction) and in situ hybridization&#xD;
      are used to analyze protein expression patterns, after proteins are identified by mass&#xD;
      spectrometry and amino acid sequencing.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3,150 patients and 1,200 healthy participants will be accrued&#xD;
      for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of tumor antigens that induce a humoral response in cancer patients</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of tumor-secreted proteins by special analysis in culture</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor-secreted protein expression in tumors and preneoplastic lesions</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential markers for early detection of cancer</measure>
  </primary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The laboratory will apply technologies for protein analysis to the detection and&#xD;
        identification of proteins secreted by tumor cells and protein antigens that induce a&#xD;
        humoral response in tumors. The initial targeted tumor types for the identification of&#xD;
        potential biomarker proteins are: Colon, esophagus, ovary, lung, breast and liver&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria (patient):&#xD;
&#xD;
               -  Scheduled to undergo primary surgical resection or first debulking surgery (prior&#xD;
                  to any anticancer treatment) for suspected or newly diagnosed cancer, including&#xD;
                  any of the following types:&#xD;
&#xD;
                    -  Breast cancer&#xD;
&#xD;
                    -  Adenocarcinoma of the colon&#xD;
&#xD;
                    -  Adenocarcinoma or squamous cell carcinoma of the esophagus&#xD;
&#xD;
                    -  Non-small cell lung cancer&#xD;
&#xD;
                    -  Ovarian epithelial adenocarcinoma&#xD;
&#xD;
               -  Metastatic or unresectable cancer, including any of the following types:&#xD;
&#xD;
                    -  Breast cancer&#xD;
&#xD;
                    -  Adenocarcinoma of the colon&#xD;
&#xD;
                    -  Adenocarcinoma or squamous cell carcinoma of the esophagus&#xD;
&#xD;
                    -  Hepatoma&#xD;
&#xD;
                    -  Non-small cell lung cancer&#xD;
&#xD;
                    -  Small cell lung cancer&#xD;
&#xD;
                    -  Ovarian epithelial adenocarcinoma&#xD;
&#xD;
                    -  Adenocarcinoma of the pancreas&#xD;
&#xD;
          -  Meets the following criteria (healthy participant):&#xD;
&#xD;
               -  No chronic disease&#xD;
&#xD;
                    -  Healthy participants with a history of cancer must be cancer-free for 5&#xD;
                       years (skin cancer or carcinoma in situ of the cervix within the past 5&#xD;
                       years allowed)&#xD;
&#xD;
               -  Willing to provide 60 mL of blood&#xD;
&#xD;
               -  Not a blood relative of an eligible and consenting cancer patient&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Able to tolerate the removal of 30-60 mL of blood&#xD;
&#xD;
          -  No feelings of light-headedness, dizziness, or fainting within the past 2 weeks&#xD;
&#xD;
          -  Pulse less than 100 on day of blood draw for study enrollment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy or radiotherapy for metastatic or&#xD;
             unresectable cancer&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir M. Hanash, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>February 5, 2012</last_update_submitted>
  <last_update_submitted_qc>February 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dr. Dean Brenner</name_title>
    <organization>University of Michigan Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>stage I esophageal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>stage I ovarian epithelial cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

